Company news
Kamada Ltd. news in 2021
Kamada Ltd.'s news releases, calls and decks from 2021, newest first.
Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products
November 21, 2021
Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products
November 21, 2021
Kamada to Announce Third Quarter Financial Results and Host Conference Call on November 22, 2021
November 7, 2021
Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities
August 10, 2021
Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021
August 4, 2021
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children
June 1, 2021
Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities
May 11, 2021
Kamada to Announce First Quarter Ended March 31, 2021 Financial Results and Host Conference Call on May 12, 2021
May 4, 2021
Kamada Announces Amendment to GLASSIA® License Agreement with Takeda
April 6, 2021
Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19)
March 30, 2021
Kamada to Present at the Jefferies Global Plasma Summit
March 8, 2021
Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.
March 2, 2021
Kamada Files Annual Report for the Year Ended December 31, 2020
February 23, 2021
Kamada Reports Fourth Quarter and Fiscal Year 2020 Financial Results, Recent Achievements and Corporate Development Activities
February 9, 2021
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2020 Financial Results, and Host Conference Call on February 10, 2021
February 2, 2021
Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA
January 31, 2021
Kamada Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel
January 12, 2021
Kamada Selected as a Winner of the Genesis Prize Foundation and Start-Up Nation Central Competition
January 4, 2021